What is the result of the AVERROES trial that compared apixaban to aspirin in AF patients?
The AVERROES trial compared apixaban 5 mg bid with aspirin in AF patients who were not candidates for VKA. The trial was stopped early for benefit as apixaban significantly reduced the risk of stroke or systemic embolism compared with aspirin (HR, 0.45; 95% CI, 0.32-0.62; P < .001). There was no significant difference in major bleeding (HR, 1.13; 95% CI, 0.74-1.75; P .57) between apixaban and aspirin.